secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001326732-24-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q1 2024 net loss $68.0M ($1.11/share); revenue down to $12.8M from $19.0M
--------------------------------------------------------------------------------

- Net loss widened to $68.0M from $60.8M YoY; diluted EPS -$1.11 vs -$1.02.
- Revenue fell to $12.8M from $19.0M; non-cash royalty revenue vs prior milestone revenue.
- Cash and marketable securities $646.7M at March 31, down from $697.4M at year-end 2023.
- First patient dosed in Phase 1 for XmAb541 (CLDN6 x CD3) in solid tumors.
- Appointed Bart Cornelissen as new CFO; expects cash runway into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000030/0001326732-24-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000030/xncr-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001326732-24-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer